Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06756308 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06756308 · ClinicalTrials.gov record · last posted 2026-08-20

A Study of Enasidenib in People With T-Cell Lymphoma

StatusActive, Not Recruiting
PhasePhase 2
Started2024-12-24
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The researchers are doing this study to find out whether enasidenib is a safe treatment for people with angioimmunoblastic T-cell lymphoma (AITL) that has an IDH2 mutation. The researchers will look at the safety of enasidenib when it is given alone or in combination with the drug rituximab.

Protocol amendment history 2 changes detected by DataLookout

2026-08-21
Enrollment closed, study ongoing
2026-08-21
Enrollment reduced: 25 → 2 participants
Trial Details
NCT Number NCT06756308
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Bristol-Myers Squibb, The Leukemia and Lymphoma Society
Conditions T-cell Lymphoma
Enrollment 2 participants
Start Date 2024-12-24
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-20